Latest News and Press Releases

60 Degrees Pharma (Nasdaq: SXTP) CEO Dr. Geoff Dow to present at HCW Conference Tuesday, Sept 9, 3:30 PM ET. Live webcast link available.

60 Degrees Pharma CEO Dr. Geoff Dow will present Sept 10 at HCW 27th Global Investment Conference; webcast and replay available on company’s investor site.

60 Degrees Pharma (Nasdaq: SXTP) Q2 2025: Supply issue cut revenue, profits rose from cash-pay sales; $1.97M cash extends runway to Mar 2026.

60 Degrees launches 8-count ARAKODA® bottles, offering weekly malaria protection for short trips. Now available via major retail pharmacies.

60 Degrees Pharma reports Q1 2025 revenue up 55% to $163.6K, gross profit up 124%, driven by Arakoda sales.

60 Degrees Pharma partners with Yale to develop tafenoquine for treating and preventing babesiosis, a severe tick-borne disease with limited treatments.

60 Degrees Pharmaceuticals (SXTP) reported 140% revenue growth in 2024, driven by Arakoda® sales. Clinical trials and market expansion efforts continue.

60 Degrees Pharmaceuticals expands tafenoquine trial for babesiosis to Brigham and Women’s, targeting severe cases with unmet medical needs.

60 Degrees Pharmaceuticals regains Nasdaq compliance after achieving a minimum closing bid price of $1.00 for 10 consecutive days.

60 Degrees Pharma Q2 2024 net product revenues doubled YoY to $125K, with an 18.3% sequential growth. Gross profit rose to $35K from a $124K loss.